The goal of this clinical trial is to test alpha lipoic acid in children undergoing hemodialysis. The main questions it aims to answer are:
* Will the use of alpha lipoic acid lower cardiovascular events in that population?
* Is the incidence of those cardiovascular events linked to the oxidative stress and endothelial dysfunction in that population?
* Will the drug cause side effects?
Participants will:
* take either one dose daily of 600mg tablet Alpha lipoic acid orally or a look-alike tablet containing no drug.
* be monitored for the occurrence of cardiovascular events (stroke, angina, etc.)
* be monitored for the occurrence of side effects
* give blood samples for testing serum levels of E-selectin biomarker and superoxide dismutase enzyme
* undergo clinical examinations (Echocardiogram, Duplex ultrasonography, Intima-Media-Thickness) Researchers will compare between the group taking alpha lipoic acid and the group taking the look-alike tablet.

Start Date01 Jan 2025

Sponsor / Collaborator

Ain Shams University

[+1]

NCT05083546 / Not yet recruitingPhase 1/2IIT

Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging

Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of California, San Francisco

NCT05713799 / Not yet recruitingPhase 2IIT

Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity

Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron [MG]) combined with a supplement (alpha-lipoic acid [ALA]) may help.
Objective:
To learn how MG and ALA can help the body process food.
Eligibility:
People aged 18 to 65 years with a body mass index between 30 and 40 kg/m2.
Design:
Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician.
The study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay.
During the clinic stays, participants will undergo many tests:
They will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin.
They will have imaging scans.
They will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe.
Participants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine.
They will log their diet, exercise, and sleep....

Start Date21 Nov 2024

Sponsor / Collaborator

National Institute of Diabetes & Digestive & Kidney Diseases

100 Clinical Results associated with Lipoic acid

100 Translational Medicine associated with Lipoic acid

100 Patents (Medical) associated with Lipoic acid

7,164

Literatures (Medical) associated with Lipoic acid

01 Dec 2025·Current Urology Reports

Management Strategies for Patients with Non-Infectious Cystitis: A Review of the Literature

Review

Author: Aqeel, Jawad ; Sawyer, Kathryn ; Gupta, Priyanka ; Zheng, Yu

PURPOSE OF REVIEWThe management of noninfectious cystitis continues to evolve as new treatments continue to be developed and investigated. This review aims to synthesize the most recent data regarding management strategies for noninfectious cystitis focused on non-ulcerative, ulcerative, eosinophilic, and ketamine-induced cystitis.RECENT FINDINGSSeveral novel treatments have shown promise as management options including combination antihistamine therapy, phosphodiesterase 5 inhibitors, alpha lipoic acid supplements, and onabotulinumtoxin A. Recent studies have also found pentosan polysulfate sodium to have adverse ophthalmologic effects. For patients with ulcerative cystitis, recent research has shown that fulguration with or without triamcinolone injections should not be delayed. The treatment of noninfectious cystitis should be patient specific based on factors including etiology and symptom profile. Multimodal regimens are often the most effective. Treatment should be started with conservative options and escalated as necessary to oral treatments, intravesical options, or procedural management.

01 Jan 2025·Methods in Molecular Biology

Nonenzymatic Oxidized Polyunsaturated Fatty Acid Products in Human Plasma and Urine Samples by LC-QTOF-MS/MS

Article

Author: Lee, Jetty Chung-Yung ; Leung, Kin Sum

Oxidative stress induces autooxidation of polyunsaturated fatty acids, producing numerous isoprostanoids and isofuranoids. These oxidized products are measurable in human plasma and urine and serve as oxidative stress biomarkers for chronic diseases. This chapter details the preparation and measurement of α-linolenic acid-derived phytoprostanes and phytofurans in human samples using liquid chromatography-quadrupole time-of-flight tandem mass spectrometry (LC-QToF-MS/MS).

01 Jan 2025·Pediatric Neurology

Biallelic Variants in LIPT2 as a Cause of Infantile-Onset Dystonia: Expanding the Clinical and Molecular Spectrum

Article

Author: Ganetzky, Rebecca ; Autio, Kaija ; Vera, Alonso Zea ; Sen, Kuntal ; Kastaniotis, Alexander ; Wongkittichote, Parith ; Puronurmi, Anna ; Gropman, Andrea

BACKGROUNDLipoyl transferase 2 is involved in the biosynthesis of lipoate. Lipoate is the cofactor for the glycine cleavage system and four dehydrogenase enzymes. Biallelic variants in LIPT2 causing severe neonatal encephalopathy was first described in 2017.METHODSClinical data were collected by retrospective chart review after obtaining consent from parents. The pathogenicity of these variants was further delineated using a yeast model. The YEp352-LIPT2 plasmid was used as a template to generate the two patient variants using QuickChange Lightning Site-Directed Mutagenesis Kit.RESULTSThe patient was a 15-month-old female who presented at one month with dystonia, developmental delay, and feeding difficulties. Brain magnetic resonance imaging showed cortical malformations including colpocephaly, polymicrogyria, and heterotopia. Patient had elevations in lactate (6.1 mmol/L) and glycine. Exome sequencing showed two variants of uncertain significance in trans in the LIPT2 gene: c.346 G>T and c.418C>T. Patient was started on lipoic acid, thiamine, and COQ10. Yeast complementation experiments indicate that both patient mutant variants result in diminished function versions of the LIPT2 protein.CONCLUSIONWe report the fourth case of LIPT2-related disorder. Proband shared significant overlap with previous patients; however, there was a distinct movement disorder and brain malformations, which have not been previously described. Unlike most neurometabolic disorders where dystonia develops later after metabolic stroke in basal ganglia, LIPT2-related disorder seems unique due to early onset of dystonia due to energy deficit in the developing brain. Lipoic acid supplementation has not led to significant clinical improvement. Analyses in yeast indicate that novel variants are deleterious but have retained some functionality.

News (Medical) associated with Lipoic acid

01 Aug 2024

·www.prnewswire.com

Livity Wellness Introduces New IV Therapy Offerings in South Florida

MIAMI, Aug. 1, 2024 /PRNewswire/ -- Livity Wellness, a pioneer in holistic health and wellness, is thrilled to announce the addition of PlaqueX and Alpha Lipoic Acid IV Therapy to its suite of services in South Florida. As one of the select providers in the region offering these treatments, Livity Wellness continues to expand its innovative intravenous therapy options, which are dedicated to promoting overall wellness and vitality. Advanced IV Therapy Solutions Continue Reading Alpha Lipoic Acid Livity Wellness is enhancing the wellness landscape with its new PlaqueX and Alpha Lipoic Acid IV Therapy. This treatment combines phosphatidylcholine (PlaqueX) and alpha lipoic acid (ALA) to offer unique health benefits that are currently under scientific investigation. Phosphatidylcholine (PlaqueX) Phosphatidylcholine is a vital component of cell membranes and is essential for cellular function. Preliminary studies suggest that PlaqueX may play a role in maintaining cardiovascular health by potentially breaking down arterial plaque, which could reduce the risk of heart disease and stroke. Additionally, it is being studied for its potential to support liver function and enhance the body's natural detoxification processes. However, it is important to note that these claims have not been evaluated or approved by the FDA, and ongoing research aims to further understand its benefits and efficacy. Alpha Lipoic Acid (ALA) Alpha Lipoic Acid is a potent antioxidant that combats oxidative stress and inflammation. Current research indicates that ALA may regenerate other critical antioxidants, such as vitamins C and E. It is also being studied for its potential to support healthy blood sugar levels and improve insulin sensitivity, which may be beneficial for individuals managing diabetes or metabolic syndrome. Like PlaqueX, the specific health claims related to ALA have not been approved by the FDA, and further studies are needed to validate its therapeutic potential. Enhanced Antioxidant Support: Adding Glutathione Livity Wellness takes IV therapy a step further by incorporating glutathione, another powerful antioxidant, into their treatments. Glutathione is known for its role in detoxifying the body, reducing oxidative stress, and supporting the immune system. The combination of glutathione with PlaqueX and ALA is intended to enhance the overall antioxidant capacity, creating a synergistic effect that may maximize cellular protection and repair. These health claims are based on preliminary research and have not been approved by the FDA, emphasizing the need for ongoing scientific exploration. Commitment to Wellness and Innovation Livity Wellness is committed to offering innovative and evidence-based treatments to its clients. By introducing PlaqueX and Alpha Lipoic Acid IV Therapy, the clinic aims to provide advanced options for those seeking to enhance their wellness journey. While the potential benefits of these therapies are promising, Livity Wellness encourages clients to stay informed about the latest research findings and to consult with healthcare professionals before starting any new treatment regimen. For more information about Livity Wellness and its IV therapy offerings, please visit our website or contact us directly. References For further reading on the research related to these therapies, please see the following sources: What Sets Livity Wellness Apart? Superior Absorption and Efficacy IV therapy at Livity Wellness delivers nutrients directly into the bloodstream, bypassing the digestive system for 100% absorption and immediate benefits. This direct infusion ensures higher concentrations and more rapid absorption than oral supplements, providing unmatched bioavailability and potency. Customized Wellness Plans Every client's journey to optimal health is unique. Livity Wellness's skilled practitioners craft personalized IV therapy plans tailored to each individual's specific needs and objectives, whether enhancing cardiovascular health, supporting liver function, or improving overall well-being. Professional Care and Safety At Livity Wellness, client safety, and comfort are paramount. Their highly trained professionals meticulously monitor the infusion process, ensuring a seamless and relaxing experience. Treatment durations and frequencies are customized to meet each client's unique health requirements. Real Stories, Real Transformations Carlos R. from Miami Beach, FL: "Livity Wellness's IV therapy has transformed my life. The personalized blends boosted my energy and improved my health. The convenience of having therapy at home is unbeatable. I highly recommend them!" Maria L. from Coral Gables, FL: "After years of chronic fatigue, Livity Wellness's IV therapy has been a revelation. I feel more energized and healthier. The team is professional and ensures a comfortable experience every time." About Livity Wellness Livity Wellness is South Florida's premier destination for holistic health and wellness optimization. Offering on-demand wellness services, including personalized IV therapy, weight loss management, and acute care treatments, Livity Wellness delivers top-tier health solutions directly to clients' doorsteps. By seamlessly blending advanced science with personalized care, Livity Wellness helps clients achieve their ultimate health and wellness goals. Contact Information: Livity Wellness Website: Phone: 786-936-3190 Email: [email protected] Address: 6303 Waterford District Dr., Miami, FL 33126 Media Contact: OmniFunnel Marketing Public Relations Manager - Livity Wellness Email: [email protected] Website: Phone: 1-866-673-9306 SOURCE Livity Wellness

03 Apr 2024

·www.prnewswire.com

Lipids with potential health benefits in herbal teas

Hokkaido University researchers have identified new lipids in some herbal teas in detail for the first time, preparing the ground for investigating their contribution to the health benefits of the teas. SAPPORO, Japan, April 3, 2024 /PRNewswire/ -- Herbal teas are enjoyed worldwide, not only for their taste and refreshment but also for a wide range of reputed health benefits. But the potential significance of a category of compounds called lipids in the teas has been relatively unexplored. Researchers at Hokkaido University, led by Associate Professor Siddabasave Gowda and Professor Shu-Ping Hui of the Faculty of Health Sciences, have now identified 341 different molecular species from five categories of lipids in samples of four types of herbal tea. They published their results in the journal Food Chemistry. Continue Reading The four types of herbal tea investigated in this study for their bioactive lipids. (Photo provided by Siddabasave Gowda) Lipids are a diverse collection of natural substances that share the property of being insoluble in water. They include all of the fats and oils that are common constituents of many foods, but they have generally not been examined as significant components of teas. The Hokkaido team selected four teas for their initial analysis: dokudami (Houttuynia cordata, fish mint), kumazasa (Sasa veitchii), sugina (Equisetum arvense, common horsetail) and yomogi (Artemisia princeps, Japanese mugwort). "These herbs are native to Japan and have been widely consumed as tea from ancient times due to their medicinal properties," says Gowda. The medicinal benefits attributed to these and other herbal teas include antioxidant, antiglycation, anti-inflammatory, antibacterial, antiviral, anti-allergic, anticarcinogenic, antithrombotic, vasodilatory, antimutagenic, and anti-aging effects. The lipids in the teas were separated and identified by combining two modern analytical techniques called high-performance liquid chromatography and linear ion trap-Orbitrap mass spectrometry. The analysis revealed significant variations in the lipids in the four types of tea, with each type containing some known bioactive lipids. These included a distinct category of lipids called short-chain fatty acid esters of hydroxy fatty acids (SFAHFAs), some of which had never previously been found in plants. SFAHFAs detected in tea could be a novel source of short-chain fatty acids, which are essential metabolites for maintaining gut health. "The discovery of these novel SFAHFAs opens new avenues for research," says Hui, adding that the lipid concentrations found in the teas are at levels that could be expected to have significant nutritional and medical effects in consumers. The lipids discovered also included α-linolenic acid, already known for its anti-inflammatory properties, and arachidonic acid which has been associated with a variety of health benefits. These two compounds are examples of a range of poly-unsaturated fatty acids found in the teas, a category of lipids that are well-known for their nutritional benefits. "Our initial study paves the way for further exploration of the role of lipids in herbal teas and their broad implications for human health and nutrition," Gowda concludes. "We now want to expand our research to characterize the lipids in more than 40 types of herbal tea in the near future." Contacts: Associate Professor Siddabasave Gowda Faculty of Health Sciences Graduate School of Global Food Resources Hokkaido University Tel: +81-11-706-3687 Email: [email protected] Professor Shu-Ping Hui Faculty of Health Sciences Hokkaido University Tel: +81-11-706-3693 Email: [email protected] Sohail Keegan Pinto (International Public Relations Specialist) Public Relations & Communications Division Office of Public Relations and Social Collaboration Hokkaido University Tel: +81-11-706-2186 Email: [email protected] Paper : Lipsa Rani Nath, et al. Dissecting new lipids and their composition in herbal tea using untargeted LC/MS. Food Chemistry. March 4, 2024 DOI: 10.1016/j.foodchem.2024.138941 Funding: This study was supported by the Japan Society for the Promotion of Science (JSPS; 22K1485002, 21H02376, 21K1481201); and the Japan Science and Technology Agency (JST) SPRING (JPMJSP2119). Press release on Hokkaido University website: Photo: SOURCE Hokkaido University

23 Oct 2023

·www.prnewswire.com

REVIVELE LAUNCHES COMPREHENSIVE WOMEN'S SUPPLEMENT SYSTEM

Essentials by Revivele Takes the Guesswork out of Women's Supplementation with a System Designed to Support Cognitive Function, Balance Hormones, and Help Prevent Disease MIAMI, Oct. 23, 2023 /PRNewswire/ -- Revivele, the pharmacist-founded healthcare company empowering women to take control of their own health, has launched Essentials by Revivele, a comprehensive, easy-to-use supplement system tailored specifically to help improve and support women's overall health and longevity, especially as they enter their perimenopausal and post-menopausal years. Continue Reading Essentials by Revivele women's supplements were developed by Dr. Kavita Desai, Pharm. D. Post this Essentials by Revivele is a comprehensive, easy-to-use supplement system tailored to help improve and support women’s overall health and longevity, especially during perimenopausal and post-menopausal years. Essentials by Revivele includes clinically proven ingredients and dosage amounts based on clinical studies linked to better long-term health outcomes and disease prevention. It is also economical and easy to use, as purchasing each ingredient as a separate supplement would require taking nearly 60 pills a day and cost more money overall. Founder Dr. Kavita Desai, Pharm. D., a Doctor of Pharmacy, brain health advocate, and published author of "Lady Parts: Putting Women's Health Back Into Women's Hands," spent over two years formulating 48 science-backed vitamins, minerals, herbs, and functional mushrooms into an efficient and thoughtfully formulated supplement system that supports women's health. Essentials by Revivele is designed to address cognitive function, longevity, hormonal balance, and common symptoms associated with perimenopause and menopause, among other preventative aspects of women's health. This strategic supplement system is also aimed at reducing the risk of chronic diseases like Alzheimer's, which affects twice as many women as men worldwide. Dr. Desai started her career as a hospital-based pharmacist, eventually opening her own integrated medical center and clinical pharmacy focused on pain management and preventative medicine. At that time in Dr. Desai's career, her mother was diagnosed with early-onset Alzheimer's. Dr. Desai learned first-hand about the many disease risks women face as they enter the perimenopausal years and how important it is for women to prioritize their own health. She pivoted her career to addressing symptom relief and disease prevention in women, with a special focus on improving brain health, and prevention of Alzheimer's and other chronic diseases. In 2021 she founded Revivele, which helps fill this gap in health care by providing tangible solutions, and is an educational resource for women. "Through running my own integrated medical center, witnessing the decline of my mother's health and hearing from thousands of women in our Revivele online community, I'm aware of the challenges women face in prioritizing themselves and their health," says Dr. Desai. "I created Essentials by Revivele to take the guesswork out of supplementation for women, help them take a proactive approach to their health, and feel their best through their perimenopausal years and beyond." The Essentials by Revivele system is comprised of six daily products carefully formulated to work in harmony and be taken throughout the day. Designed for enhanced tolerability and absorption, Essentials aims to help improve all facets of women's health, especially focusing on cognitive function, energy, sleep, mood, gut health, immunity and hormone balance. The products include: Inhale (enteric-coated tablets) – A blend of herbs, vitamins, and minerals for improved energy production, reducing inflammation, burning fat, and boosting brain function. Key ingredients: Vitamin C, B-vitamins, choline, selenium, chromium, inositol, berberine, coenzyme Q10, whole coffee fruit extract, ashwagandha, alpha lipoic acid. Flow (enteric-coated tablets) – A midday adaptogenic supplement designed for the ups and downs of a busy day. Flow helps to boost brain function, regulate energy and blood sugar, help the body cope with physical and chemical stressors, and boost immunity. Key ingredients: zinc, Ceylon cinnamon, berberine, ashwagandha, tulsi/holy basil, turmeric, piperine, rhodiola. Enhance (soft-gels) – A rich mix of high-dose Omega-3 fish oils and vital fat-soluble vitamins designed for maximum absorption. These soft gels work to strengthen heart and brain functions, as well as improve mood, skin, and bone health. Key ingredients: Vitamin D₃, vitamin E, vitamin K₂-MK7, Omega-3 fatty acids (EPA, DHA). Bloom (gummies) – An exclusive blend of seven functional mushrooms that are a tasty way to supercharge the immune system, boost energy levels, bolster daily resilience, reduce inflammation, while also improving brain and digestive functions. Naturally colored and flavored, these gummies have a delicious lemon soda taste, and are sugar-free. Key ingredients: Maitake, cordyceps, lion's mane, reishi, wild chaga, tremella, turkey tail mushrooms. Flourish (capsules) – Consists of 48 billion beneficial microbes that work to strengthen the gut's lining, improving digestion and absorption of nutrients. This proprietary probiotic blend will help improve many dimensions of overall health. Key ingredients: Proprietary blend consisting of seven unique probiotic strains. Exhale (capsules) – Fosters a relaxing and restorative sleep for body and mind alike. Encourages muscle relaxation and a reset of sleep cycles to enhance immune function and restore brain function. Key ingredients: Magnesium glycinate, L-theanine, melatonin. "I'm proud that Essentials by Revivele greatly surpasses all other products on the market today, which often contain too few key ingredients needed to make a meaningful impact on one's health," said Dr. Kavita Desai, Pharm. D., Founder and CEO, Revivele. "Because a piecemeal approach to supplementation can be confusing, expensive and ineffective, I meticulously formulated this comprehensive supplement system to be easy to follow and offer maximum absorption and efficacy to support a woman's health throughout all the decades of her adult life." At launch, a 30-day supply of Essentials by Revivele is available at Revivele.com, for $399, which equates to approximately $13 per day. For more information about Revivele and Dr. Desai, visit Revivele.com, or check out @Revivele.Inc on Instagram, Revivele.Inc on Facebook, and Revivele on LinkedIn. About Revivele Revivele is a female-focused healthcare brand dedicated to women's long-term health, perimenopausal support and overall disease prevention. Founded by accomplished pharmacist, published author, and women's health specialist, Dr. Kavita Desai, Pharm.D., the company's mission is to help fill the gap in health care and empower women to take control of their own well-being. Dr. Desai created Revivele to build a sense of community for women, provide compassionate, factual information, and actionable solutions to help improve their health outcomes and better advocate for their needs. Women face challenges that men don't – which is why Revivele provides female-led, research-focused health information and solutions to help women live their best, healthiest lives in the present and future. Alafair Hall [email protected] 415-730-9044 SOURCE Revivele

100 Deals associated with Lipoic acid

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lipoic acid	A10B	DB00166

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic Neuropathies	DE	-	01 Jan 1966

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Neuropathies	Phase 1	IT	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetic Neuropathies	Phase 1	GB	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetic Neuropathies	Phase 1	SE	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetic Neuropathies	Phase 1	US	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetic Neuropathies	Phase 1	NL	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetes Mellitus	Phase 1	CN	NovaMed Pharmaceuticals, Inc.	-
Diabetic Neuropathies	Preclinical	HR	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetic Neuropathies	Preclinical	FR	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetic Neuropathies	Preclinical	DK	MEDA Pharma GmbH & Co. KG	01 May 1998
Diabetic Neuropathies	Preclinical	ES	MEDA Pharma GmbH & Co. KG	01 May 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01054768 (CTgov)	Phase 2	Inflammation \| Anemia, Sickle Cell	37	alpha-lipoic acid+acetyl-L-carnitine (Alpha-lipoic Acid and Acetyl-L-carnitine)	(dqwknqrpsp) = ebqxfxgyyt fegxrrazil (zazbqisbfx, elcazgazbb - gdgqjyzzxw) View more	-	03 Aug 2021
				Control (Placebo)	(dqwknqrpsp) = imkorxpihz fegxrrazil (zazbqisbfx, dffgnisetm - iggquwdngg) View more
EASD2020	Not Applicable	Diabetic Neuropathies	-	Benfotiamine 300 mg/day	flxpzuzwfv(wvdgthfszs) = esniqibhfd bzapzbismv (krkzsawihg ) View more	-	24 Sep 2020
				Alpha-lipoic acid 600 mg/day	flxpzuzwfv(wvdgthfszs) = rorzhbyblp bzapzbismv (krkzsawihg ) View more
NCT00962429 (CTgov)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	7	lipoic acid (Lipoic Acid)	zbybgfliiq(tthfhcjomm) = kjqgodguli wydmmbbudr (qhhrqcwvaj, qvfcnvozow - tagjdlckhf) View more	-	19 Aug 2020
				lipoic acid (Placebo)	zbybgfliiq(tthfhcjomm) = fsipbykwsq wydmmbbudr (qhhrqcwvaj, dfsozweeye - clzluvbzqm) View more
ISRCTN13159380 (Pubmed \| Oxid Med Cell Longev)	Phase 2/3	Diabetes Mellitus, Type 2	135	Experimental group (600 mg/day ALA)	thnodwnahr(dcexzirvse) = nbgorcwezt nkeiatjets (vakmnqkaej )	-	01 Jan 2019
				Alpha-lipoic Acid (Placebo group)	thnodwnahr(dcexzirvse) = lpfagnqcfq nkeiatjets (vakmnqkaej )
ESPE2018	Not Applicable	Metabolic Syndrome	44	α-lipoic acid	(cpmbcfhsqd) = There is no side effect of α-lipoic acid in children inkwqgqjfe (tvzojzfmut )	Positive	27 Sep 2018
				Alpha-lipoic Acid
2018 ARVO Annual Meeting (ARVO2018)	Not Applicable	interleukin (IL) \| interferon (IFN) \| tumor necrosis factor (TNF)	-	Hyaluronic acid	(ngcbqjzewd) = fpkfkstasl sgfqamrfny (psyunqwhwg )	-	01 Jul 2018
				Lipoic acid	(ngcbqjzewd) = vzqwbbleoy sgfqamrfny (psyunqwhwg )
Pubmed	Phase 4	Insulin Resistance	32	ALA 400 mg b.i.d.	lbvcwjvruy(chmgvvumop) = fztmprvpjx epfqkefgej (whkvzlwaqj, 0.36 - 0.70)	-	01 Mar 2018
NCT01188811 (Pubmed \| Neurol Neuroimmunol Neuroinflamm)	Phase 2/3	Multiple Sclerosis, Secondary Progressive	54	Lipoic acid 1,200 mg	mlrzrlvpge(nzqunksprs): P-Value = 0.002 View more	Positive	01 Sep 2017
				Placebo
NCT02133664 (CTgov)	Phase 1/2	Cognition \| Cognitive Dysfunction \| Multiple Sclerosis	54	omega-3 fatty acids+lipoic acid (Lipoic Acid and Omega-3 Fatty Acids)	mspatgrwjt(smgozhzhxv) = mzsicukeej tsgukrbyaw (hrognqvler, qoryspuciu - rnttwhvabg) View more	-	03 May 2017
				Placebo (Placebo)	mspatgrwjt(smgozhzhxv) = bjmvptgikj tsgukrbyaw (hrognqvler, nkeqgrobvk - vddzhzzrbp) View more
NCT01058941 (CTgov)	Phase 1/2	Alzheimer Disease	67	Lipoic acid+fish oil concentrate (Lipoic Acid and Omega-3 Fatty Acids)	hrifftcvfm(tltigtrraa) = epwctjeewy vwtehtclgz (kqpvuaowxd, btvnddaykl - xvsikzcnga) View more	-	13 Apr 2017
				Placebo (Placebo)	hrifftcvfm(tltigtrraa) = watxzmfebs vwtehtclgz (kqpvuaowxd, rghbjzemez - lnbvzygulv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis